{"id":745631,"date":"2018-11-28T16:30:00","date_gmt":"2018-11-28T16:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/"},"modified":"2025-11-07T01:26:51","modified_gmt":"2025-11-07T06:26:51","slug":"european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/","title":{"rendered":"European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in&#8230;"},"content":{"rendered":"<p class=\"bwalignc\">       Approvals Based on Findings from the Pivotal Phase 3 DRIVE-AHEAD and        DRIVE-FORWARD Trials Evaluating the Efficacy and Safety of DELSTRIGO and        PIFELTRO Through 96 Weeks     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the European Commission has approved DELSTRIGO\u2122 and<br \/>\n      PIFELTRO\u2122 for the treatment of HIV-1 infection. DELSTRIGO is a new<br \/>\n      once-daily fixed-dose combination tablet of doravirine (100 mg),<br \/>\n      lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg<sup>[1]<\/sup>).<br \/>\n      It is indicated in the European Union for the treatment of adults with<br \/>\n      HIV-1 infection without past or present evidence of resistance to the<br \/>\n      non-nucleoside reverse transcriptase inhibitor (NNRTI) class of<br \/>\n      antiviral agents, lamivudine or tenofovir.<b> <\/b>PIFELTRO (doravirine,<br \/>\n      100 mg) is a new, once-daily NNRTI indicated (in the EU) in combination<br \/>\n      with other antiretroviral medicines for the treatment of adults with<br \/>\n      HIV-1 infection without past or present evidence of resistance to the<br \/>\n      NNRTI class.\n    <\/p>\n<p>\n      In the United States, both DELSTRIGO and PIFELTRO are indicated for the<br \/>\n      treatment of HIV-1 infection in adults with no prior antiretroviral<br \/>\n      treatment experience, and are administered orally once daily with or<br \/>\n      without food.<b> <\/b>DELSTRIGO contains a boxed warning regarding<br \/>\n      post-treatment acute exacerbations of hepatitis B (HBV) infection.<br \/>\n      DELSTRIGO and PIFELTRO do not cure HIV-1 infection or AIDS.\n    <\/p>\n<p>\n      \u201cWe are very pleased that the European Commission has approved DELSTRIGO<br \/>\n      and PIFELTRO, as this approval marks another important milestone in<br \/>\n      Merck\u2019s unwavering commitment to the global HIV community,\u201d said Dr.<br \/>\n      George Hanna, vice president and therapeutic area head of infectious<br \/>\n      diseases, Global Clinical Development, Merck Research Laboratories.<br \/>\n      \u201cThese medicines bring new treatment options with demonstrated efficacy<br \/>\n      that could potentially address unmet needs for people in Europe living<br \/>\n      with HIV.\u201d\n    <\/p>\n<p>\n      The approval allows for marketing of DELSTRIGO and PIFELTRO in all 28<br \/>\n      European Union member states, plus Iceland, Lichtenstein and Norway, and<br \/>\n      follows a positive opinion from the Committee for Medicinal Products for<br \/>\n      Human Use of the European Medicines Agency announced on Sept. 20, 2018.<br \/>\n      Marketing authorization applications for DELSTRIGO and PIFELTRO are also<br \/>\n      under review in other countries, including Australia and Switzerland.<br \/>\n      The U.S. Food and Drug Administration approved DELSTRIGO and PIFELTRO on<br \/>\n      Aug. 30, 2018. Health Canada approved PIFELTRO on Oct. 12, 2018 and<br \/>\n      DELSTRIGO on Nov. 9, 2018. Availability for DELSTRIGO and PIFELTRO in<br \/>\n      the EU is anticipated to begin in the first half of 2019.\n    <\/p>\n<p>\n      \u201cAs a practitioner serving people living with HIV, I welcome new<br \/>\n      medicines that can help us tailor HIV treatment regimens to the needs of<br \/>\n      the individual,\u201d said Dr. Esteban Mart\u00ednez, senior consultant and<br \/>\n      associate professor of medicine, infectious diseases, University of<br \/>\n      Barcelona, Spain. \u201cThe approvals of DELSTRIGO and PIFELTRO bring<br \/>\n      important new treatment options to market which have shown demonstrated<br \/>\n      efficacy and low rates of discontinuation.\u201d\n    <\/p>\n<p>\n      <b>Data Supporting the Approvals of DELSTRIGO and PIFELTRO in the<br \/>\n      European Union<\/b>\n    <\/p>\n<p>\n      The approval from the European Commission was based on data from two<br \/>\n      pivotal, randomized, multicenter, double-blind, active controlled Phase<br \/>\n      3 trials, DRIVE-AHEAD and DRIVE-FORWARD, evaluating the efficacy and<br \/>\n      safety of DELSTRIGO and PIFELTRO, respectively, in participants infected<br \/>\n      with HIV-1 with no prior antiretroviral treatment history. Across both<br \/>\n      of the studies, 25.4 percent of the participants were based in Europe<br \/>\n      (379\/1494).\n    <\/p>\n<p>\n      In DRIVE-AHEAD, DELSTRIGO met its primary endpoint, demonstrating<br \/>\n      non-inferior efficacy compared to efavirenz (EFV)\/emtricitabine<br \/>\n      (FTC)\/tenofovir disoproxil fumarate (TDF) at 48 weeks (84% in the<br \/>\n      DELSTRIGO group achieved viral suppression of HIV-1 RNA &lt;40 copies\/mL<br \/>\n      vs. 80% in the EFV\/FTC\/TDF group; treatment difference: 4.1%, 95%<br \/>\n      confidence interval: -1.5, 9.7). The Week 96 data were supportive of the<br \/>\n      Week 48 findings. At Week 96, 76% in the DELSTRIGO group achieved viral<br \/>\n      suppression of HIV-1 RNA &lt;40 copies\/mL vs. 73% in the EFV\/FTC\/TDF group;<br \/>\n      treatment difference: 3.3%, 95% confidence interval: -3.1, 9.6. The rate<br \/>\n      of discontinuation of treatment due to adverse events was lower in the<br \/>\n      DELSTRIGO treatment group than in the EFV\/FTC\/TDF treatment group, 3%<br \/>\n      and 6.6% respectively.&nbsp;Clinical adverse reactions of all grades<br \/>\n      occurring in \u22655 percent of participants in the DELSTRIGO treatment group<br \/>\n      included nausea (6%) and headache (5%).\n    <\/p>\n<p>\n      In DRIVE-FORWARD, PIFELTRO met its primary endpoint, demonstrating<br \/>\n      non-inferior efficacy compared to darunavir + ritonavir (DRV+r), each in<br \/>\n      combination with FTC\/TDF or abacavir (ABC)\/3TC at 48 weeks (83% in the<br \/>\n      PIFELTRO group achieved viral suppression of HIV-1 RNA &lt;40 copies\/mL vs.<br \/>\n      79% in the DRV+r group; treatment difference: 4.2%, 95% confidence<br \/>\n      interval: -1.4, 9.7). The Week 96 data were supportive of the Week 48<br \/>\n      findings. At week 96, 72% in the PIFELTRO group achieved viral<br \/>\n      suppression of HIV-1 RNA &lt;40 copies\/mL vs. 64% in the DRV+r group;<br \/>\n      treatment difference: 7.6%, 95% confidence interval: 1.0, 14.2.&nbsp;In a<br \/>\n      pooled analysis combining data from two clinical trials of<br \/>\n      treatment-na\u00efve participants (P007 and P021\/DRIVE-AHEAD), fewer<br \/>\n      participants in the combined doravirine (100 mg) treatment groups (2.8%)<br \/>\n      discontinued due to an adverse event by week 48 compared with the<br \/>\n      combined EFV treatment group (6.1%) (treatment difference -3.4%,<br \/>\n      p=0.012). Clinical adverse reactions of all grades occurring in \u22655<br \/>\n      percent of participants in the PIFELTRO treatment group included nausea<br \/>\n      (6%) and headache (5%).\n    <\/p>\n<p>\n      <b>Selected Safety Information about DELSTRIGO (doravirine\/3TC\/TDF) in<br \/>\n      the U.S.<\/b>\n    <\/p>\n<p>\n      <i>Warning: Post treatment Acute Exacerbation of Hepatitis B (HBV)<\/i>\n    <\/p>\n<p>\n      All patients with HIV-1 should be tested for the presence of HBV before<br \/>\n      initiating antiretroviral therapy.<b> <\/b>Severe acute exacerbations of<br \/>\n      HBV have been reported in patients who are coinfected with HIV-1 and HBV<br \/>\n      and have discontinued products containing lamivudine or TDF, which are<br \/>\n      components of DELSTRIGO. Patients coinfected with HIV-1 and HBV who<br \/>\n      discontinue DELSTRIGO should be monitored with both clinical and<br \/>\n      laboratory follow-up for at least several months after stopping<br \/>\n      DELSTRIGO.<b> <\/b>If appropriate, initiation of anti-HBV therapy may be<br \/>\n      warranted.\n    <\/p>\n<p>\n      DELSTRIGO is contraindicated when co-administered with drugs that are<br \/>\n      strong cytochrome P450 (CYP)3A enzyme inducers (including the<br \/>\n      anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and<br \/>\n      phenytoin; the androgen receptor inhibitor enzalutamide; the<br \/>\n      antimycobacterials rifampin and rifapentine; the cytotoxic agent<br \/>\n      mitotane; and the herbal product St. John\u2019s wort (Hypericum<br \/>\n      perforatum)), as significant decreases in doravirine plasma<br \/>\n      concentrations may occur, which may decrease the effectiveness of<br \/>\n      DELSTRIGO. DELSTRIGO is contraindicated in patients with a previous<br \/>\n      hypersensitivity reaction to lamivudine.\n    <\/p>\n<p>\n      Renal impairment, including cases of acute renal failure and Fanconi<br \/>\n      syndrome, have been reported with the use of TDF.<b> <\/b>DELSTRIGO<br \/>\n      should be avoided with concurrent or recent use of a nephrotoxic agent,<br \/>\n      as cases of acute renal failure after initiation of high-dose or<br \/>\n      multiple NSAIDs have been reported in patients with risk factors for<br \/>\n      renal dysfunction who appeared stable on TDF.\n    <\/p>\n<p>\n      Prior to or when initiating DELSTRIGO, and during treatment, assess<br \/>\n      serum creatinine, estimated creatinine clearance, urine glucose and<br \/>\n      urine protein in all patients.<b> <\/b>In patients with chronic kidney<br \/>\n      disease, also assess serum phosphorus.<b> <\/b>Discontinue DELSTRIGO in<br \/>\n      patients who develop clinically significant decreases in renal function<br \/>\n      or evidence of Fanconi syndrome.<b> <\/b>Discontinue DELSTRIGO if<br \/>\n      estimated creatinine clearance declines below 50 mL\/min.\n    <\/p>\n<p>\n      In clinical trials in HIV-1 infected adults, TDF was associated with<br \/>\n      slightly greater decreases in bone mineral density (BMD) and increases<br \/>\n      in biochemical markers of bone metabolism. Serum parathyroid hormone<br \/>\n      levels and 1,25 vitamin D levels were also higher. Cases of osteomalacia<br \/>\n      associated with proximal renal tubulopathy have been reported with the<br \/>\n      use of TDF.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment.<b> <\/b>Because DELSTRIGO is a complete<br \/>\n      regimen, co-administration with other antiretroviral medications for the<br \/>\n      treatment of HIV-1 infection is not recommended.\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions.\n    <\/p>\n<p>\n      If co-administered with rifabutin, take one tablet of DELSTRIGO once<br \/>\n      daily, followed by one tablet of doravirine (PIFELTRO) approximately 12<br \/>\n      hours after the dose of DELSTRIGO.<b> <\/b>The most common adverse<br \/>\n      reactions with DELSTRIGO (incidence \u22655%, all intensities) were dizziness<br \/>\n      (7%), nausea (5%) and abnormal dreams (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to DELSTRIGO during pregnancy. Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263. Mothers infected<br \/>\n      with HIV-1 should be instructed not to breastfeed if they are receiving<br \/>\n      DELSTRIGO due to the potential for HIV-1 transmission. Because DELSTRIGO<br \/>\n      is a fixed-dose combination tablet and the components cannot be altered,<br \/>\n      it is not recommended in patients with estimated creatinine clearance<br \/>\n      less than 50 mL\/min.\n    <\/p>\n<p>\n      <b>Selected Safety Information about PIFELTRO (doravirine) in the U.S.<\/b>\n    <\/p>\n<p>\n      PIFELTRO is contraindicated when co-administered with drugs that are<br \/>\n      strong cytochrome P450 (CYP)3A enzyme inducers (including the<br \/>\n      anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and<br \/>\n      phenytoin; the androgen receptor inhibitor enzalutamide; the<br \/>\n      antimycobacterials rifampin and rifapentine; the cytotoxic agent<br \/>\n      mitotane; and the herbal product St. John\u2019s wort (Hypericum<br \/>\n      perforatum)), as significant decreases in PIFELTRO plasma concentrations<br \/>\n      may occur, which may decrease the effectiveness of PIFELTRO.<b> <\/b>Immune<br \/>\n      reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment.<b> <\/b>Co-administration of PIFELTRO<br \/>\n      with efavirenz, etravirine or nevirapine is not recommended.<b> <\/b>If<br \/>\n      co-administered with rifabutin, increase PIFELTRO dosage to one tablet<br \/>\n      twice daily (approximately 12 hours apart).\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions.<b> <\/b>The safety of<br \/>\n      PIFELTRO is based on two studies, DRIVE-FORWARD and DRIVE-AHEAD.<b> <\/b>In<br \/>\n      DRIVE-FORWARD, the most common adverse reactions (incidence \u22655%, all<br \/>\n      intensities) were nausea (7%), headache (6%), fatigue (6%), diarrhea<br \/>\n      (5%) and abdominal pain (5%).<b> <\/b>In DRIVE-AHEAD, the most common<br \/>\n      adverse reactions (incidence \u22655%, all intensities) were dizziness (7%),<br \/>\n      abnormal dreams (5%) and nausea (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to PIFELTRO during pregnancy.<b> <\/b>Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263.<b> <\/b>Mothers<br \/>\n      infected with HIV-1 should be instructed not to breastfeed if they are<br \/>\n      receiving PIFELTRO due to the potential for HIV transmission.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for DELSTRIGO (doravirine\/3TC\/TDF)<br \/>\n      at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and Patient Information for DELSTRIGO (doravirine\/3TC\/TDF) at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for PIFELTRO (doravirine) at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and Patient Information for PIFELTRO (doravirine) at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      <sup>[1]<\/sup> Equivalent to 245 mg of tenofovir disoproxil\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele<br \/>(267) 305-3558     <\/p>\n<p>       Sarra S. Herzog<br \/>(908) 740-1871     <\/p>\n<p>       Investor:<br \/>Teri Loxam<br \/>(908) 740-1986     <\/p>\n<p>       Michael DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved DELSTRIGO\u2122 and PIFELTRO\u2122 for the treatment of HIV-1 infection. DELSTRIGO is a new once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg [1] ). It is indicated in the European Union for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiviral agents, lamivudine or tenofovir. PIFELTRO (doravirine, 100 mg) is a new, once-daily NNRTI indicated (in the EU) in combination with other antiretroviral medicines for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the NNRTI class. In the United States, both DELSTRIGO and PIFELTRO are indicated for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745631","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in... - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in... - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved DELSTRIGO\u2122 and PIFELTRO\u2122 for the treatment of HIV-1 infection. DELSTRIGO is a new once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg [1] ). It is indicated in the European Union for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiviral agents, lamivudine or tenofovir. PIFELTRO (doravirine, 100 mg) is a new, once-daily NNRTI indicated (in the EU) in combination with other antiretroviral medicines for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the NNRTI class. In the United States, both DELSTRIGO and PIFELTRO are indicated for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\\\/\",\"name\":\"European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \\\/ lamivudine \\\/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in... - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2018-11-28T16:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \\\/ lamivudine \\\/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in&#8230;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in... - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/","og_locale":"en_US","og_type":"article","og_title":"European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in... - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved DELSTRIGO\u2122 and PIFELTRO\u2122 for the treatment of HIV-1 infection. DELSTRIGO is a new once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg [1] ). It is indicated in the European Union for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiviral agents, lamivudine or tenofovir. PIFELTRO (doravirine, 100 mg) is a new, once-daily NNRTI indicated (in the EU) in combination with other antiretroviral medicines for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the NNRTI class. In the United States, both DELSTRIGO and PIFELTRO are indicated for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:51+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/","name":"European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in... - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2018-11-28T16:30:00+00:00","dateModified":"2025-11-07T06:26:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-commission-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"European Commission Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in&#8230;"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"67f1e62e-17ca-468a-91b3-53b8493fd2f5","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/European-Commission-Approves-Mercks-DELSTRIGO-doravirine--lamivudine--tenofovir-disoproxil-fumarate-a-Once-Daily-Fixed-Dose-Combinati-20R3D.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745631\/revisions"}],"predecessor-version":[{"id":3674987,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745631\/revisions\/3674987"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745631"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}